Skip to main navigation

Main navigation

About Us
Commitments
- Innovation Hub
Products
Partnerships
- Grants
- Partnerships for the Future
News
- In The News
- Archive
Investors
Sustainability
Careers

Home
Investors
In the News
Archive
Events

Archived News Releases

Keyword Search

Year

Pacira BioSciences Reports Preliminary Unaudited Total Revenue for 2022 of $666.8 Million

01/05/23

Pacira BioSciences to Present at the 41st Annual J.P. Morgan Healthcare Conference

01/04/23

Shareholder Tools

RSS Feeds
Email Alerts

Contact Us
Legal
Site Map
Privacy Notice

EXPAREL^® (bupivacaine liposome injectable suspension), iovera^o, ZILRETTA^® (triamcinolone acetonide extended-release injectable suspension), and Pacira are registered trademarks of the respective subsidiaries of Pacira BioSciences, Inc. All other trademarks referenced herein are the property of their respective owners.